H.C. Wainwright Reaffirms Their Buy Rating on OncoSec Medical

By Ryan Adsit

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on OncoSec Medical (NASDAQ: ONCS), with a price target of $4. The company’s shares closed on Friday at $1.57.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -7.9% and a 35.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Currently, the analyst consensus on OncoSec Medical is Moderate Buy and the average price target is $4.50, representing a 186.6% upside.

In a report issued on April 16, Maxim Group also maintained a Buy rating on the stock with a $5 price target.

Based on OncoSec Medical’s latest earnings report for the quarter ending January 31, the company posted quarterly revenue of $0 and GAAP net loss of $10.74 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $5.39 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications. The company was founded by Avtar S. Dhillon, Punit S.